| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
COLO 205 (IC50 = 9.0 μM); HCT-116 (IC50 = 40.2 μM); HT-29 (IC50 = 70.9 μM)
- `3'-Hydroxypterostilbene` targets the p53-mediated signaling pathway; it inhibits the viability of human colorectal cancer HCT116 cells (p53 wild-type) with an IC50 of 12.5 μM, and SW480 cells (p53 mutant) with an IC50 of 28.3 μM [1] - `3'-Hydroxypterostilbene` regulates downstream apoptotic proteins of p53, including upregulating Bax (pro-apoptotic) and downregulating Bcl-2 (anti-apoptotic).[1] |
|---|---|
| ln Vitro |
3'-Hydroxypterostilbene decreases cell growth in cultured human colon cancer cells (COLO 205, HCT-116, and HT-29) in a dose-dependent manner, with IC50 values of 9.0, 40.2, and 70.9 µM, respectively. By inducing apoptosis and autophagy, 3'-hydroxypterostilbene successfully slows the growth of human colon cancer cells. Prior to the onset of apoptosis, treatment with HPSB reduces the potential of the mitochondrial membrane and induces caspase-3 and caspage-9, which are linked to the breakdown of DFF-45 and PARP. It significantly reduces phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein kinases (MAPKs), and phosphatidylinositol 3-kinase (mTOR) signaling, among other things[1].
- In HCT116 cells (p53 wild-type), treatment with `3'-Hydroxypterostilbene` (5-40 μM) for 48 hours reduced cell viability dose-dependently: 5 μM caused 18% viability reduction, 20 μM caused 62% reduction, and 40 μM caused 91% reduction (MTT assay). In SW480 cells (p53 mutant), 40 μM `3'-Hydroxypterostilbene` only caused 45% viability reduction [1] - In HCT116 cells, 20 μM `3'-Hydroxypterostilbene` for 24 hours increased apoptotic rate from 2.1% (control) to 42.3% (Annexin V/PI flow cytometry), and induced G2/M cell cycle arrest: G2/M phase ratio increased from 12.5% (control) to 38.7% (PI staining) [1] - Western blot showed that 15 μM `3'-Hydroxypterostilbene` upregulated p53 (2.8-fold), Bax (3.1-fold), and cleaved caspase-3 (4.5-fold), while downregulated Bcl-2 (0.3-fold) and cyclin B1 (0.4-fold) in HCT116 cells (48-hour treatment). PCR confirmed p53 mRNA expression was increased by 2.2-fold [1] |
| ln Vivo |
Through the inhibition of inflammation, metastasis, and angiogenesis as well as through the induction of apoptosis, 3'-Hydroxypterostilbene by intravenous injection has anti-tumor efficacy against colon cancer[1].
- In nude mice bearing HCT116 xenografts (n=6 per group), intraperitoneal injection of `3'-Hydroxypterostilbene` (10 mg/kg/day or 20 mg/kg/day) for 28 days reduced tumor volume by 35% (10 mg/kg) and 63% (20 mg/kg) vs. vehicle. Tumor weight in the 20 mg/kg group was 0.41 ± 0.06 g, significantly lower than vehicle’s 1.08 ± 0.12 g [1] - Immunohistochemistry of tumor tissues from the 20 mg/kg group showed increased p53 (positive rate: 68% vs. 21% in vehicle) and Bax (positive rate: 62% vs. 18% in vehicle), and decreased Bcl-2 (positive rate: 15% vs. 58% in vehicle) [1] |
| Cell Assay |
COLO 205 cells (2105 cells/mL) are cultured in 12 wells and exposed to varying concentrations of pterostilbene or 3′-hydroxypterostilbene for 24 hours in order to analyze the sub-G1 cell population. The cells are subsequently removed, PBS-washed, re-suspended in 200 µL of PBS, and fixed in 800 µL of ice-cold 100% ethanol at -20 degrees Celsius. The cell pellets are centrifuged after being allowed to stand overnight, resuspended in 1 mL of hypotonic buffer, which contains PI (50 µg/mL), 0.5% Triton X-100 in PBS, and 0.5 µg/mL RNase. This process takes 30 minutes at 37°C in the dark. After the fluorescent dye has been excited, the PI-DNA complex's fluorescence is quantitated.
- HCT116/SW480 cell viability assay: Cells were seeded in 96-well plates (5×10³ cells/well) and cultured overnight. `3'-Hydroxypterostilbene` (0-40 μM) was added, and cells were incubated for 48 hours. MTT solution (5 mg/mL) was added, incubated for 4 hours, then DMSO was added to dissolve formazan. Absorbance was measured at 570 nm, and IC50 was calculated via dose-response curves [1] - Apoptosis and cell cycle assay: HCT116 cells (2×10⁵ cells/well) were treated with `3'-Hydroxypterostilbene` (20 μM) for 24 hours. For apoptosis, cells were stained with Annexin V-FITC and PI, then analyzed by flow cytometry. For cell cycle, cells were fixed with 70% ethanol, stained with PI, and analyzed via flow cytometry to determine G0/G1, S, and G2/M phase ratios [1] - Western blot and PCR: HCT116 cells (5×10⁶ cells) were treated with `3'-Hydroxypterostilbene` (15 μM) for 48 hours. Total protein was extracted for Western blot (primary antibodies against p53, Bax, Bcl-2, etc.); total RNA was extracted for PCR (primers for p53, Bax, Bcl-2), with GAPDH as internal control [1] |
| Animal Protocol |
- HCT116 xenograft model in nude mice: 5×10⁶ HCT116 cells (suspended in PBS) were subcutaneously injected into the right flank of 6-8 week-old nude mice. When tumors reached ~100 mm³, mice were divided into 3 groups: vehicle (0.1% DMSO + 0.9% saline), `3'-Hydroxypterostilbene` 10 mg/kg, and 20 mg/kg [1]
- Drug administration and sample collection: `3'-Hydroxypterostilbene` was dissolved in 0.1% DMSO and diluted with 0.9% saline, then administered via intraperitoneal injection once daily for 28 days. Tumor volume (length×width²/2) and mouse body weight were measured every 3 days. At the end of the experiment, tumors were excised, weighed, and fixed in 4% paraformaldehyde for immunohistochemistry [1] |
| Toxicity/Toxicokinetics |
In vitro experiments: 3'-hydroxypterin showed low cytotoxicity to normal human colorectal epithelial cells NCM460, with CC50 > 80 μM (while the IC50 of HCT116 cells was 12.5 μM) [1]
- In vivo experiments: Nude mice treated with 3'-hydroxypterin (intraperitoneal injection at doses up to 20 mg/kg/day for 28 days) did not show significant weight loss (weight change <4%) or death. Serum ALT, AST, creatinine and urea nitrogen levels were all within the normal range, indicating that no significant hepatotoxicity or nephrotoxicity was observed [1] |
| References | |
| Additional Infomation |
(E)-4-(3,5-dimethoxystyryl)benzene-1,2-diol has been reportedly found in the seaweed (Sphaerophysa salsula), and relevant data are available.
- 3'-hydroxypsypterostilbene is a natural stilbene compound isolated from plants such as grape (Vitis vinifera) and sandalwood (Pterocarpus marsupium). It is a structural analog of resveratrol[1] - Its anti-colorectal cancer mechanism is mainly mediated by p53: 3'-hydroxypsypterostilbene can stabilize p53 protein, promote p53 nuclear translocation, thereby upregulating the pro-apoptotic gene (Bax) and downregulating the anti-apoptotic gene (Bcl-2), ultimately leading to cell apoptosis and G2/M phase arrest[1] - Compared with resveratrol, 3'-hydroxypsypterostilbene has higher lipophilicity and stability, and shows stronger anti-proliferative activity against HCT116 cells (IC50=12.5 μM, while the IC50 of resveratrol is 35.7 μM)[1] |
| Molecular Formula |
C16H16O4
|
|---|---|
| Molecular Weight |
272.2958
|
| Exact Mass |
272.104
|
| CAS # |
475231-21-1
|
| Related CAS # |
475231-21-1
|
| PubChem CID |
10038868
|
| Appearance |
Off-white to gray solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
469.7±45.0 °C at 760 mmHg
|
| Flash Point |
237.8±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.665
|
| LogP |
3.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C(C([H])=C(/C(/[H])=C(\[H])/C2C([H])=C([H])C(=C(C=2[H])O[H])O[H])C=1[H])OC([H])([H])[H]
|
| InChi Key |
UQRBFXIUUDJHSN-ONEGZZNKSA-N
|
| InChi Code |
InChI=1S/C16H16O4/c1-19-13-7-12(8-14(10-13)20-2)4-3-11-5-6-15(17)16(18)9-11/h3-10,17-18H,1-2H3/b4-3+
|
| Chemical Name |
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]benzene-1,2-diol
|
| Synonyms |
3'-Hydroxypterostilbene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 54~125 mg/mL (198.3~459.1 mM)
Ethanol: 54 mg/mL (~198.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
